Aclaris Therapeutics Inc (NASDAQ:ACRS) hit a new 52-week low on Monday . The company traded as low as $5.41 and last traded at $5.51, with a volume of 821310 shares trading hands. The stock had previously closed at $6.03.

A number of brokerages recently weighed in on ACRS. ValuEngine raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 target price on shares of Aclaris Therapeutics in a research note on Friday, March 22nd. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 19th. Finally, BidaskClub downgraded shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $30.58.

The company has a market capitalization of $252.16 million, a P/E ratio of -1.37 and a beta of 1.23. The company has a current ratio of 6.57, a quick ratio of 6.54 and a debt-to-equity ratio of 0.14.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.03). The business had revenue of $3.67 million for the quarter, compared to analysts’ expectations of $4.40 million. Aclaris Therapeutics had a negative return on equity of 72.13% and a negative net margin of 1,315.41%. As a group, analysts anticipate that Aclaris Therapeutics Inc will post -2.67 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of ACRS. Citigroup Inc. raised its stake in shares of Aclaris Therapeutics by 3,200.0% during the fourth quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 3,872 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $43,000. Legal & General Group Plc raised its stake in shares of Aclaris Therapeutics by 64.1% during the fourth quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,536 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Aclaris Therapeutics during the first quarter worth approximately $70,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Aclaris Therapeutics by 493.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,078 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 10,043 shares in the last quarter. 94.65% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2019/04/15/aclaris-therapeutics-acrs-hits-new-52-week-low-at-5-41.html.

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: Price to Earnings Ratio (PE)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.